Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
1,178.80
+3.30 (0.28%)
Oct 29, 2026, 12:00 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 80.17B INR in the quarter ending June 30, 2026, with 21.96% growth. This brings the company's total for the last twelve months to 285.92B, up 21.11% year-over-year. In the fiscal year ending March 31, 2026, Zydus Lifesciences had annual revenue of 271.48B with 16.81% growth. That makes Zydus Lifesciences the 3,804th largest company in the world by revenue and 105th in India.
Revenue (ttm)
285.92B
Revenue Growth
+21.11%
P/S Ratio
4.10
Revenue / Employee
9.54M
Employees
29,980
Market Cap
1.18T
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Zydus Lifesciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 271.48B | 39.07B | 16.81% |
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 349.35B |
| Cipla | 280.68B |
| Glenmark Pharmaceuticals | 177.37B |
| Mankind Pharma | 153.47B |
| Alkem Laboratories | 150.81B |
| Divi's Laboratories | 112.30B |
| Ipca Laboratories | 101.26B |
| Emcure Pharmaceuticals | 96.83B |
Zydus Lifesciences News
- 15 days ago - USFDA accepts biosimilar application of Zydus and German firm for Keytruda - The Times of India
- 15 days ago - FDA Accepts BLA For Formycon And Zydus' Keytruda Biosimilar FYB206 ;Shares Rise - Nasdaq
- 5 weeks ago - Zydus Lifesciences proposes ₹1,000cr university near Ahmedabad - The Times of India
- 2 months ago - Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics - Nasdaq
- 2 months ago - Zydus Life Q1 PAT falls 36% to Rs 940 crore as revenue rises 22% - The Times of India
- 2 months ago - Zydus Lifesciences Transcript: Q1 26/27 - Transcripts
- 2 months ago - Zydus Lifesciences Quarterly report: Q1 2027 - Filings
- 2 months ago - Zydus Lifesciences Slides: Q1 2027 - Filings